Story

Definium Therapeutics Stock Surges 20% on Positive Phase 3 Anxiety Drug Trial Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Definium Therapeutics Stock Surges 20% on Positive Phase 3 Anxiety Drug Trial Data
Text size
Background

Definium Therapeutics (NASDAQ:DFTX) shares surged 20% in Wednesday's pre-market trading after the company announced positive topline results from its Phase 3 Voyage study. The trial, which evaluated the drug candidate DT120 ODT for treating generalized anxiety disorder (GAD), successfully met its primary endpoint and all key secondary efficacy endpoints.

Trial Meets All Endpoints

The study's primary endpoint was the change in the Hamilton Anxiety Rating Scale (HAM-A) score from baseline. According to Definium, participants receiving DT120 ODT achieved a statistically significant reduction in their HAM-A score compared to those on placebo.

The company reported a placebo-adjusted change of -5.4 points from baseline at Week 12, a result with high statistical significance (p<0.0001). The mean change from baseline was -11.6 for the DT120 ODT group, compared with -6.2 for the placebo group. The treatment also demonstrated rapid efficacy, with improvements observed as early as Day 2 and sustained throughout the trial.

Sample IUX Markets – In-articleAd

Safety Profile and Next Steps

DT120 ODT was generally well tolerated in the study, which enrolled 214 participants across approximately 35 sites in the United States. Treatment-emergent adverse events were reported as mild to moderate in severity and transient. Importantly, Definium stated that no new safety signals were identified, and there was no evidence of a suicidality signal or suicidal behavior.

For investors, this marks the second positive Phase 3 readout for the DT120 ODT program. In June, the company announced positive results for the drug candidate in a trial for major depressive disorder. Definium expects topline results from its second Phase 3 study in GAD, called Panorama, in September, which will be a key upcoming catalyst for the company.

Read next

More on Stocks
Back to latest news

LATEST